SCHEMBL5016607

SCHEMBL5016607

O=C(Nc1ccc([N+](=O)[O-])cn1)c1cccc(Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
MAPT P10636 5/20 0.61
HTT P42858 1/20 0.61
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
GAA P10253 2/20 0.60
KMT2A Q03164 6/20 0.59
MEN1 O00255 4/20 0.59
LMNA P02545 1/20 0.59
STAT3 P40763 1/20 0.59
CYP1A2 P05177 1/20 0.56
RECQL P46063 1/20 0.56
PKM P14618 1/20 0.55
TSHR P16473 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
GRM5 P41594 1/20 0.53
KCNQ3 O43525 1/20 0.53
KCNQ2 O43526 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30354766 0.85 RAB9A (0.65) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL29151264 0.85 RAB9A (0.65) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL30354939 0.85 RAB9A (0.65) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL5025455 0.85 RAB9A (0.65) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL5651517 0.85 STAT3 (0.61) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL2664545 0.84 NPC1 (0.71) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL30354968 0.84 NPC1 (0.71) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL3165548 0.83 RAB9A (0.77) ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL30354767 0.82 PTGS1 (0.67) ALDH1A1MAPTHTTNPC1RAB9A
SCHEMBL29151324 0.82 PTGS1 (0.67) ALDH1A1MAPTHTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113061098-B Amide compound and derivative thereof, preparation method, pharmaceutical composition and application 中国药科大学 2022-08-30 CN disclosed
CN-113061098-A Amide compound and derivative thereof, preparation method, pharmaceutical composition and application 中国药科大学 2021-07-02 CN disclosed
EP-1575966-B1 THERAPEUTIC QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2008-10-29 EP disclosed
US-20060058325-A1 Therapeutic quniazoline derivatives ASTRAZENECA AB (SE) 2006-03-16 US disclosed
EP-1575966-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2005-09-21 EP disclosed
WO-2004058782-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058325-A1 Therapeutic quniazoline derivatives NQO2, ABL1, CYP3A7 ALDH1A1 1955/4885MAPT 751/4885HTT 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.